

# ForPatients

by Roche

Diabetic Macular Edema

## A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME)

**Trial Status**  
Recruiting

**Trial Runs In**  
2 Countries

**Trial Identifier**  
NCT06847854 BP44175

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

This study will assess the safety and tolerability of RO7497372 in participants with DME. The study consists of 2 parts. Part 1 will test multiple-ascending doses of RO7497372 after unilateral intravitreal (IVT) administration in participants with DME. The main purpose of Part 1 is to provide data for RO7497372 safety and tolerability, as well as to characterize the ocular and systemic pharmacokinetics (PK), systemic anti-drug antibodies (ADA), and duration of target engagement, i.e., the pharmacodynamics (PD) in aqueous humor (AH) and blood. Part 2 will evaluate the safety, tolerability, PK, and PD of two dose strengths of RO7497372 (low dose and high dose), identified as safe and tolerated in Part 1.

**Genentech, Inc.**  
Sponsor

**Phase 1**  
Phase

---

**NCT06847854 BP44175**  
Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**  
All

**Age**  
>=18 Years

**Healthy Volunteers**  
No

---